Biopharmaceutical Entrepreneur Jeff Aronin Helps Improve the Lives of Patients
Pledging to accelerate biomedical research and scientific breakthroughs, Paragon Biosciences specializes in investing and incubating biotech startups that bring new medicines to market. Specifically, the company nurtures, cultivates and finances new companies to set up important biotechnology innovations that will treat rare diseases.
Jeff Aronin, the current chairman and chief executive of Paragon Biosciences, has nearly 20 years of experience developing worldwide biotech and healthcare companies with the goal of working to address the unmet needs of patients. Aronin serves as the chairman of a number of Paragon portfolio companies (Gazetteday).
The privately-held Paragon’s portfolio includes innovative biotech companies such as Castle Creek Pharmaceuticals and Harmony Biosciences. Harmony, for example, focuses on developing treatments for central nervous system disorders, evaluating the potential of a novel, first-in-class compound that may be able to address narcolepsy and cataplexy in a new way.
Aronin and the team at Paragon Biosciences make good use of their expertise. They have successfully achieved 13 new drug approvals through the Food and Drug Administration, which is on par or better than many larger biotech and pharma companies.
Jeff Aronin supports philanthropic causes too. He supports the Susan G. Komen Organization, the Juvenile Diabetes Research Foundation, the Cystic Fibrosis Foundation, the Pediatric Sun Protection Foundation, and more. Aronin is also a firm believer in education and contributes to Teaching Tolerance, the Jewish National Fund, Anti-Defamation League, the Boys and Girls Club of Chicago, America’s Cup Endeavor, and the Chicago Parks Foundation.